SEC Form 4 · accession 0001626176-15-000003
Sagent Pharmaceuticals, Inc. · SGNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jan 22, 2015
Accepted (ET)
Jan 26, 2015 · 10:18 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001369786
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Jan 22, 2015 | S | 150,000 | $25.4876 | D | 3,286,976 | I | See footnote |
| Common StockF1,F2,F3 | Jan 23, 2015 | S | 61,883 | $25.9023 | D | 3,225,093 | I | see footnotes |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of Common Stock owned by certain funds (each, a "Fund" and collectively, the "Funds") and certain separately managed accounts managed by the undersigned.
- F2The shares reported are held of record by Stormlaunch & Co., Sailorshell & Co., Stormbay & Co., Sotrmstar & Co., Weyerhaeuser Company Master Retirement Trust, Sailorpier & Co., Factory Mutual Insuarance Company and Nuclear Electric Insurance Limited.
- F3The reported securities are held directly by the Funds and certain separately managed accounts managed by each of the reporting persons. Morgan Stanley Investment Management Inc., ("MSIM") is the investment manager of one or more of the separately managed accounts and Morgan Stanley AIP GP LP ("AIP") is the investment manager of one or more of the Funds. This form is filed without prejudice to the reporting persons' position that none of the Funds nor any subsidiaries of the reporting persons, nor the reporting persons individually or in aggregate, are required to file beneficial ownership reports under Section 16(a) of the Securities Exchange Act of 1934, and should not be construed or interpreted as a concession or admission that such reports are required.